TRACON Pharmaceuticals (NASDAQ:TCON) Shares Up 16.3% on Insider Buying Activity

Shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) shot up 16.3% on Wednesday after an insider bought additional shares in the company. The stock traded as high as $5.41 and last traded at $5.27. 2,072,873 shares were traded during trading, an increase of 153% from the average session volume of 817,856 shares. The stock had previously closed at $4.53.

Specifically, major shareholder Opaleye Management Inc. bought 302,150 shares of the business’s stock in a transaction on Monday, August 31st. The shares were purchased at an average cost of $1.76 per share, with a total value of $531,784.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Mark C. Wiggins bought 7,000 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were bought at an average cost of $4.14 per share, for a total transaction of $28,980.00. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 856,801 shares of company stock worth $1,845,423. 3.51% of the stock is currently owned by company insiders.

TCON has been the topic of several recent research reports. ValuEngine raised TRACON Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday. HC Wainwright lifted their target price on TRACON Pharmaceuticals from $4.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Zacks Investment Research downgraded TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 13th.

The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.62 and a current ratio of 1.62. The stock has a 50-day moving average of $2.35 and a two-hundred day moving average of $2.02. The company has a market cap of $63.17 million, a P/E ratio of -1.22 and a beta of 1.95.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.70) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.04. As a group, sell-side analysts forecast that TRACON Pharmaceuticals Inc will post -2.81 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Dowling & Yahnke LLC purchased a new position in TRACON Pharmaceuticals in the first quarter worth about $26,000. Wedbush Securities Inc. purchased a new position in shares of TRACON Pharmaceuticals during the second quarter valued at approximately $50,000. JPMorgan Chase & Co. purchased a new position in shares of TRACON Pharmaceuticals during the first quarter valued at approximately $57,000. Two Sigma Investments LP purchased a new position in shares of TRACON Pharmaceuticals during the first quarter valued at approximately $61,000. Finally, Virtu Financial LLC purchased a new position in shares of TRACON Pharmaceuticals during the second quarter valued at approximately $76,000. 18.30% of the stock is owned by institutional investors and hedge funds.

TRACON Pharmaceuticals Company Profile (NASDAQ:TCON)

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD.

Further Reading: What member countries make up the G-20?

Receive News & Ratings for TRACON Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Next Post

Global Silanes Market is Projected to Grow at a CAGR of 5.83% during period 2020-2026 -Blueweave Consulting

Fri Sep 18 , 2020
The MarketWatch News Department was not involved in the creation of this content. Sep 16, 2020 (Market Insight Reports) — According to Blueweaves Consulting, the Global Silanes Market worth is expected to reach USD 2.47 billion in 2026 from the USD 2.19 billion in 2019, at CAGR of 5.83% during […]
Global B2B Telecommunication Market 2020 by Manufacture, Size, Share, Industry Outlook and Survey 2025